(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/30326 A1

(51) International Patent Classification[7]: A61K 31/00, 31/192, 31/353, 31/44, A61P 11/00

(21) International Application Number: PCT/EP00/10076

(22) International Filing Date: 13 October 2000 (13.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/160,415 19 October 1999 (19.10.1999) US

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; 124 Grenzacherstrasse, CH-4070 Basle (CH).

(72) Inventors: BELLONI, Paula, Nanette; 2900 Tunitas Creek Road, Half Moon Bay, CA 94019 (US). KLAUS, Michael; 6 Am Hellenrain, 79576 Weil am Rhein (DE).

(74) Agent: KJELLSAA-BERGER, Hanny; 124 Grenzacherstrasse, CH-4070 Basle (CH).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*
— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/30326 A1

(54) Title: TREATMENT OF EMPHYSEMA USING RAR SELECTIVE RETINOID AGONISTS

(57) Abstract: This invention provides the use of RARγ selective agonists for the manufacture of a medicament containing one or more such agonists for the treatment of emphysema and other diseases associated with alveolar damage. In another aspect, this invention provides the use of RAR agonists, preferably a RARγ selective agonist for the manufacture of medicaments for promoting tropoelastin gene expression and alveolar matrix repair.